Long noncoding RNAs play key roles in cancer and are at the vanguard of precision therapeutic development. These efforts depend on large and high-confidence collections of cancer lncRNAs. Here we present the Cancer LncRNA Census 2 (CLC2): at 492 cancer lncRNAs, it is 4-fold greater than its predecessor, without compromising on strict criteria of confident functional / genetic roles and inclusion in the GENCODE annotation scheme. This increase was enabled by leveraging high-throughput transposon insertional mutagenesis (TIM) screening data, yielding 95 novel cancer lncRNAs. CLC2 makes a valuable addition to existing collections: it is amongst the largest, holds the greatest number of unique genes, and carries functional labels (oncogene / tumour suppressor). Analysis of this dataset reveals that cancer lncRNAs are impacted by germline variants, somatic mutations, and changes in expression consistent with inferred disease functions. Furthermore, we show how clinical / genomic features can be used to vet prospective gene sets from high-throughput sources. The combination of size and quality makes CLC2 a foundation for precision medicine, demonstrating cancer lncRNAs' evolutionary and clinical significance.

中文翻译：

---

癌症LncRNA普查2（CLC2）：增强的资源揭示了癌症lncRNA的临床特征

长的非编码RNA在癌症中起着关键作用，并且处于精确治疗开发的先锋地位。这些努力取决于癌症lncRNA的大量和高可信度集合。在这里，我们介绍了癌症LncRNA人口普查2（CLC2）：在492个癌症lncRNA处，它比其前任大4倍，同时又不影响自信的功能/遗传角色以及纳入GENCODE注释方案的严格标准。这种增加是通过利用高通量转座子插入诱变（TIM）筛选数据实现的，可产生95种新型癌症lncRNA。CLC2是现有集合的重要补充：它是最大的集合之一，拥有最多数量的独特基因，并带有功能性标记（癌基因/肿瘤抑制物）。对这个数据集的分析表明，癌症lncRNA受种系变体的影响，体细胞突变和表达变化与推断的疾病功能一致。此外，我们展示了如何使用临床/基因组特征来审查来自高通量来源的预期基因集。大小和质量的结合使CLC2成为精密医学的基础，证明了癌lncRNA的进化和临床意义。